Beam Therapeutics BEAM Change in fair value of contingent consideration
Change in fair value of contingent consideration at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's change in fair value of contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's change in fair value of contingent consideration?
- Beam Therapeutics (BEAM) reported change in fair value of contingent consideration of -$514K in Q1 2026.
- How has Beam Therapeutics's change in fair value of contingent consideration changed year-over-year?
- Beam Therapeutics's change in fair value of contingent consideration decreased by 2003.7% year-over-year, from $27K to -$514K.
- What is the long-term trend for Beam Therapeutics's change in fair value of contingent consideration?
- Over 2 years (2022 to 2024), Beam Therapeutics's change in fair value of contingent consideration has grown at a -70.7% compound annual growth rate (CAGR), from -$18.9M to -$1.62M.
- What does change in fair value of contingent consideration mean?
- Measures the non-cash change in the fair value of liabilities related to potential future payments for business acquisitions. These payments are typically triggered by the achievement of specific performance or regulatory milestones. Tracking this provides visibility into the potential future financial obligations tied to past strategic growth initiatives.